Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15 [Yahoo! Finance]
Longboard Pharmaceuticals, Inc. (LBPH)
Company Research
Source: Yahoo! Finance
Data will be featured in an encore presentation at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) LA JOLLA, Calif., April 03, 2024 BUSINESS WIRE Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Dr. Randall Kaye, Longboard's Chief Medical Officer, will present late-breaking data from the PACIFIC Study evaluating bexicaserin, an oral, centrally acting 5-HT2C receptor superagonist, in participants with Developmental and Epileptic Encephalopathies (DEEs) at the AAN Annual Meeting taking place April 13-18, 2024, virtually and in Denver, Colorado. PRESENTATION DETAILS Title: Efficacy and Safety of Bexicaserin (LP352) in Adolescent and Adult Patients with Developmental and Epileptic Encephalopathies (DEEs): Results of the Phase 1b/2a PACIFIC Study Session: Emerging Science Session (ES1) Event Type: Scien
Show less
Read more
Impact Snapshot
Event Time:
LBPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LBPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LBPH alerts
High impacting Longboard Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
LBPH
News
- Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.MarketBeat
- Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $60.00 price target on the stock.MarketBeat
- Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15Business Wire
- Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business Wire
- Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) is a favorite amongst institutional investors who own 50% [Yahoo! Finance]Yahoo! Finance
LBPH
Earnings
- 11/2/23 - Beat
LBPH
Sec Filings
- 4/15/24 - Form 8-K
- 4/12/24 - Form ARS
- 4/12/24 - Form DEFA14A
- LBPH's page on the SEC website